Cyclic GMP signaling in cardiovascular pathophysiology and therapeutics

Emily J. Tsai, David A Kass

Research output: Contribution to journalArticle

Abstract

Cyclic guanosine 3',5'-monophosphate (cGMP) mediates a wide spectrum of physiologic processes in multiple cell types within the cardiovascular system. Dysfunctional signaling at any step of the cascade - cGMP synthesis, effector activation, or catabolism - have been implicated in numerous cardiovascular diseases, ranging from hypertension to atherosclerosis to cardiac hypertrophy and heart failure. In this review, we outline each step of the cGMP signaling cascade and discuss its regulation and physiologic effects within the cardiovascular system. In addition, we illustrate how cGMP signaling becomes dysregulated in specific cardiovascular disease states. The ubiquitous role cGMP plays in cardiac physiology and pathophysiology presents great opportunities for pharmacologic modulation of the cGMP signal in the treatment of cardiovascular diseases. We detail the various therapeutic interventional strategies that have been developed or are in development, summarizing relevant preclinical and clinical studies.

Original languageEnglish (US)
Pages (from-to)216-238
Number of pages23
JournalPharmacology and Therapeutics
Volume122
Issue number3
DOIs
StatePublished - Jun 2009

Fingerprint

Cyclic GMP
Cardiovascular Diseases
Cardiovascular System
Therapeutics
Heart Failure
Cardiomegaly
Atherosclerosis
Hypertension

Keywords

  • Cardiovascular disease
  • cGMP
  • Natriuretic peptide receptor
  • Phosphodiesterases
  • PKG
  • Soluble guanylyl cyclase

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Cyclic GMP signaling in cardiovascular pathophysiology and therapeutics. / Tsai, Emily J.; Kass, David A.

In: Pharmacology and Therapeutics, Vol. 122, No. 3, 06.2009, p. 216-238.

Research output: Contribution to journalArticle

@article{441cdf0d08b646d88da9c22f56463102,
title = "Cyclic GMP signaling in cardiovascular pathophysiology and therapeutics",
abstract = "Cyclic guanosine 3',5'-monophosphate (cGMP) mediates a wide spectrum of physiologic processes in multiple cell types within the cardiovascular system. Dysfunctional signaling at any step of the cascade - cGMP synthesis, effector activation, or catabolism - have been implicated in numerous cardiovascular diseases, ranging from hypertension to atherosclerosis to cardiac hypertrophy and heart failure. In this review, we outline each step of the cGMP signaling cascade and discuss its regulation and physiologic effects within the cardiovascular system. In addition, we illustrate how cGMP signaling becomes dysregulated in specific cardiovascular disease states. The ubiquitous role cGMP plays in cardiac physiology and pathophysiology presents great opportunities for pharmacologic modulation of the cGMP signal in the treatment of cardiovascular diseases. We detail the various therapeutic interventional strategies that have been developed or are in development, summarizing relevant preclinical and clinical studies.",
keywords = "Cardiovascular disease, cGMP, Natriuretic peptide receptor, Phosphodiesterases, PKG, Soluble guanylyl cyclase",
author = "Tsai, {Emily J.} and Kass, {David A}",
year = "2009",
month = "6",
doi = "10.1016/j.pharmthera.2009.02.009",
language = "English (US)",
volume = "122",
pages = "216--238",
journal = "Pharmacology and Therapeutics",
issn = "0163-7258",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Cyclic GMP signaling in cardiovascular pathophysiology and therapeutics

AU - Tsai, Emily J.

AU - Kass, David A

PY - 2009/6

Y1 - 2009/6

N2 - Cyclic guanosine 3',5'-monophosphate (cGMP) mediates a wide spectrum of physiologic processes in multiple cell types within the cardiovascular system. Dysfunctional signaling at any step of the cascade - cGMP synthesis, effector activation, or catabolism - have been implicated in numerous cardiovascular diseases, ranging from hypertension to atherosclerosis to cardiac hypertrophy and heart failure. In this review, we outline each step of the cGMP signaling cascade and discuss its regulation and physiologic effects within the cardiovascular system. In addition, we illustrate how cGMP signaling becomes dysregulated in specific cardiovascular disease states. The ubiquitous role cGMP plays in cardiac physiology and pathophysiology presents great opportunities for pharmacologic modulation of the cGMP signal in the treatment of cardiovascular diseases. We detail the various therapeutic interventional strategies that have been developed or are in development, summarizing relevant preclinical and clinical studies.

AB - Cyclic guanosine 3',5'-monophosphate (cGMP) mediates a wide spectrum of physiologic processes in multiple cell types within the cardiovascular system. Dysfunctional signaling at any step of the cascade - cGMP synthesis, effector activation, or catabolism - have been implicated in numerous cardiovascular diseases, ranging from hypertension to atherosclerosis to cardiac hypertrophy and heart failure. In this review, we outline each step of the cGMP signaling cascade and discuss its regulation and physiologic effects within the cardiovascular system. In addition, we illustrate how cGMP signaling becomes dysregulated in specific cardiovascular disease states. The ubiquitous role cGMP plays in cardiac physiology and pathophysiology presents great opportunities for pharmacologic modulation of the cGMP signal in the treatment of cardiovascular diseases. We detail the various therapeutic interventional strategies that have been developed or are in development, summarizing relevant preclinical and clinical studies.

KW - Cardiovascular disease

KW - cGMP

KW - Natriuretic peptide receptor

KW - Phosphodiesterases

KW - PKG

KW - Soluble guanylyl cyclase

UR - http://www.scopus.com/inward/record.url?scp=67349149420&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67349149420&partnerID=8YFLogxK

U2 - 10.1016/j.pharmthera.2009.02.009

DO - 10.1016/j.pharmthera.2009.02.009

M3 - Article

C2 - 19306895

AN - SCOPUS:67349149420

VL - 122

SP - 216

EP - 238

JO - Pharmacology and Therapeutics

JF - Pharmacology and Therapeutics

SN - 0163-7258

IS - 3

ER -